For the Focus Section on Pharmacogenetics
PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics†
Article first published online: 10 MAR 2008
© 2008 Wiley-Liss, Inc.
Special Issue: Focus on Pharmacogenetics
Volume 29, Issue 4, pages 456–460, April 2008
How to Cite
Owen, R. P., Altman, R. B. and Klein, T. E. (2008), PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum. Mutat., 29: 456–460. doi: 10.1002/humu.20731
- Issue published online: 10 MAR 2008
- Article first published online: 10 MAR 2008
- Manuscript Accepted: 9 DEC 2007
- Manuscript Received: 24 JUL 2007
- National Institutes of Health (NIH)
- National Institute of General Medical Sciences (NIGMS). Grant Number: UO1GM61374
PharmGKB, the pharmacogenetics and pharmacogenomics knowledge base (www.pharmgkb.org) is a publicly available online resource dedicated to the dissemination of how genetic variation leads to variation in drug responses. The goals of PharmGKB are to describe relationships between genes, drugs, and diseases, and to generate knowledge to catalyze pharmacogenetic and pharmacogenomic research. PharmGKB delivers knowledge in the form of curated literature annotations, drug pathway diagrams, and very important pharmacogene (VIP) summaries. Recently, PharmGKB has embraced a new role—broker of pharmacogenomic data for data sharing consortia. In particular, we have helped create the International Warfarin Pharmacogenetics Consortium (IWPC), which is devoted to pooling genotype and phenotype data relevant to the anticoagulant warfarin. PharmGKB has embraced the challenge of continuing to maintain its original mission while taking an active role in the formation of pharmacogenetic consortia. Hum Mutat 29(4), 456–460, 2008. © 2008 Wiley-Liss, Inc.